See the latest news and media coverage for Clario. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical trial endpoint technology and services provider
clario.comLast updated
In short: Clario was acquired by Thermo Fisher Scientific for $8.875 billion, completed in March 2026.
The AI team applied scientific expertise to head-and-neck cancer analysis using multimodal data, winning against 120 teams. Congratulations to Joël Schaerer and colleagues for this recognition.
This acquisition integrates R&D capabilities into Clario's portfolio, expanding its services in radiopharmaceutical imaging.
The ECG Mirror Participant tool identifies duplicate or mislabeled electrocardiograms, strengthening data oversight and sponsor confidence in drug safety assessments.
The deal values Clario at $8.875 billion in cash, plus potential earnouts. It aims to provide pharma and biotech customers with deeper clinical insights.
Casper said Clario provides technology for generating and managing clinical-trial endpoints and will be combined with Thermo Fisher’s central laboratory capabilities to support sponsors, clinical...
'The sale to Thermo Fisher Scientific was the single biggest full exit in private equity globally announced last year,'
Thermo Fisher Scientific raised its 2026 revenue forecast to $47.3-$48.1 billion and adjusted EPS to $24.64-$25.12 after a strong first quarter and the completion of...
Life sciences company Thermo Fisher (NYSE:TMO) reported Q1 CY2026 results , with sales up 6.2% year on year to $11.01 billion. Its non-GAAP profit of...
Track Clario and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.
